| Strategy | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | Expected Key Milestones |
|---|---|---|---|---|---|---|
| FcRn+ | ||||||
| Thyroid Eye Disease (TED) | spiriTED | Phase 2b topline data expected in 2025 | ||||
| Thyroid Eye Disease (TED) | Phase 3 expected to begin in H2 2024 | |||||
| Cardiovascular Inflammation | ||||||
| Atherosclerotic Cardiovascular Disease (ASCVD) |
| Phase 2 topline data expected in H1 2025 | ||||
| FcRn+ | |||
| Thyroid Eye Disease (TED) | |||
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
spiriTED | |||
| Expected Key Milestone: Phase 2b topline data expected in 2025 | |||
| FcRn+ | |||
| Thyroid Eye Disease (TED) | |||
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
| Expected Key Milestone: Phase 3 expected to begin in H2 2024 | |||
| Cardiovascular Inflammation | |||
| Atherosclerotic Cardiovascular Disease (ASCVD) | |||
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
| |||
| Expected Key Milestone: Phase 2 topline data expected in H1 2025 | |||
Expect to announce at least one additional indication in 2024
Note: Hatched bars represent trials that have not yet commenced
As part of our FcRn+ strategy, our initial indication is Thyroid Eye Disease (TED), an autoimmune disease characterized by autoantibodies that target orbital fibroblasts and adipocytes in the eye, causing inflammation and disfigurement which can be sight-threatening in severe cases.
For our cardiovascular inflammation strategy, we are focused on atherosclerotic cardiovascular disease (ASCVD). ASCVD is a leading cause of death globally and preventing major cardiovascular events (MACE) represents a significant goal to improve global health outcomes.
We continue to seek additional opportunities for TOUR006. We continue to identify indications where IL-6 inhibition has shown evidence of clinical benefit despite no formal industry-led development programs as well as indications where we could bring TOUR006’s differentiated profile forward, capitalizing on external de-risking events.
For more information about our expanded access policy, please view here.
